Skip to main content
BT

Byongen Therapeutics

The company develops next-generation adeno-associated virus (AAV) gene delivery vectors through capsid modification. These modified AAV vectors provide precise and safe in vivo gene delivery for gene therapy applications.

Beijing, China
Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Features

  • The company develops next-generation adeno-associated virus (AAV) gene delivery vectors through capsid modification. These modified AAV vectors provide precise and safe in vivo gene delivery for gene therapy applications.
This profile is AI-generated and may contain inaccuracies.